Source: Platinex.
  • Platinex (PTX) closes acquisition of Ontario gold assets
  • The company also completed the binding heads of agreement with Fancamp Exploration 
  • The company raised $2,119,540 at $0.04 per unit by issuing 52,187,797 units
  • Each unit is comprised of one common share of the Platinex and one-half of one common share purchase warrant
  • Platinex trades on the CSE and creates shareholder value through the opportunistic acquisition
  • Platinex (PTX) is up 12.50 per cent, trading at C$0.05


Platinex (PTX) completed the previously announced private placement raising $2,700,840.

Also worth noting is how Platinex completed the binding heads of agreement with Fancamp Exploration (TSXV: FNC).

Closing of acquisition details

This was due to the company advancing the exploration and development of certain gold mineral properties owned by the parties in the Timmins, Ontario, mining camp.

Greg Ferron, President and Chief Executive Officer of Platinex, added his thoughts on the acquisition. “We look forward to Fancamp’s input on Platinex’s board, as a joint venture partner and as a member of the South Timmins technical committee.”

“We are excited to advance the South Timmins joint venture projects, both of which are extremely well situated. Exploration plans for 2023 are being developed, and we will provide an update as those plans are finalized,” concluded Ferron.

The company raised $2,119,540 at $0.04 per unit by issuing 52,187,797 units. 

Each unit is comprised of one common share of the Platinex and one-half of one common share purchase warrant.

Platinex trades on the CSE and creates shareholder value through the opportunistic acquisition and advancement of high-quality projects in prolific Ontario mining camps.

Platinex (PTX) is up 12.50 per cent, trading at C$0.05.

More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.